# Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

> **NCT03710876** · PHASE3 · COMPLETED · sponsor: **Ferring Ventures Limited** · enrollment: 53 (actual)

## Conditions studied

- Malignant Pleural Mesothelioma

## Interventions

- **BIOLOGICAL:** rAd-IFN
- **DRUG:** Celecoxib Oral Product
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT03710876
- **Lead sponsor:** Ferring Ventures Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-21
- **Primary completion:** 2024-03-29
- **Final completion:** 2026-01-16
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03710876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03710876, "Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03710876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*